Neal Walker compensation by year
Aclaris Therapeutics Summary Compensation Table · all 8 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $510,000 | $550,000 | $499,875 | $423,784 | $566,500 | $589,680 | $477,431 | $615,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Stock awards | $0 | $954,288 | $2,434,518 | $535,830 | $1,758,786 | $1,434,240 | $170,400 | $828,426 |
| Option awards | $0 | $2,626,344 | $0 | $231,784 | $4,130,564 | $3,446,799 | $421,586 | $1,581,615 |
| Non-equity incentive | $288,150 | $221,100 | $203,940 | $407,880 | $387,486 | $353,808 | $372,396 | $350,550 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 |
| All other | $11,436 | $11,660 | $11,688 | $11,868 | $11,600 | $12,200 | $3,322 | $0 |
| Total | $809,586 | $4,363,392 | $3,150,021 | $1,611,146 | $6,854,936 | $5,836,727 | $1,445,135 | $3,375,591 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 23, 2026, accession 0001104659-26-047262, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001104659-26-047262. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 253,900 | $764,239 | — |
| RSU | 59,184 | $178,144 | — |
| Option | 888,800 | — | $2.40 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Aclaris Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Neal Walker · this page | Chief Executive Officer | $3,375,591 |
| Kevin Balthaser | Chief Financial Officer | $1,490,790 |
| James Loerop | Chief Business Officer | $1,447,106 |
Board service
Aclaris Therapeutics board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $0 | $0 | $0 | $0 | — |
| FY2024 | — | — | — | — | — |
| FY2023 | $73,500 | $0 | $0 | — | $73,500 |
| FY2022 | — | — | — | — | — |
| FY2021 | — | — | — | — | — |
Each year as the company reported it in Aclaris Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Aclaris Therapeutics pays directors a $40,000 cash retainer and $320,000 in Stock Options and RSUs. As stated in Aclaris Therapeutics's FY2025 proxy.
The full Aclaris Therapeutics compensation record
free company briefThis page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Aclaris Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Aclaris Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ACRS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.